Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16388357 | 0.83 | CALM1 (0.48) | MEN1KMT2ALTA4HCYP2C19CHRM2 | |
| SCHEMBL509904 | 0.83 | MEN1 (0.47) | MEN1KMT2ACYP2C19 | |
| SCHEMBL28341270 | 0.82 | ALDH1A1 (0.55) | MEN1KMT2AHDAC8HDAC6 | |
| SCHEMBL21153197 | 0.77 | MAOA (0.63) | MAOACA2HDAC8HDAC6 | |
| SCHEMBL366283 | 0.76 | CYP2C19 (0.62) | MEN1KMT2ACYP2C19 | |
| Fluoride SCHEMBL634375 | 0.76 | MEN1 (0.74) | MEN1KMT2ATDP1BCHEMAOA | |
| SCHEMBL10054993 | 0.76 | MEN1 (0.74) | MEN1KMT2ATDP1BCHEMAOA | |
| SCHEMBL18259873 | 0.76 | NPC1 (0.58) | MEN1KMT2ACA1CA2 | |
| SCHEMBL5799878 | 0.73 | MEN1 (0.78) | MEN1KMT2ATDP1BCHEMAOA | |
| Benzene SCHEMBL11697595 | 0.73 | MEN1 (0.78) | MEN1KMT2ATDP1BCHEMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | ACELOT,INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | ACELOT, INC. | 2020-07-16 | — | — | US | disclosed |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | ACELOT, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | ACELOT, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | APP, PSEN2, PSEN1 | MEN1 1428/4885KMT2A 4242/4885TDP1 395/4885 |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | APP, PSEN2, PSEN1 | MEN1 1060/4885KMT2A 3426/4885TDP1 467/4885 |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | APP, PSEN2, PSEN1 | MEN1 1428/4885KMT2A 4242/4885TDP1 395/4885 |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | HTT, TARDBP, SNCA | MEN1 4558/4885KMT2A 4255/4885TDP1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.